Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis
Fang Jianwen,
Yu Tianze,
Jiang Xiaocong,
Lu Yuexin,
Shang Xi,
Shen Haixing,
Lu Yue,
Zheng Jingyan,
Fu Peifen
Affiliations
Fang Jianwen
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
Yu Tianze
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
Jiang Xiaocong
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
Lu Yuexin
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
Shang Xi
Department of Breast and Thyroid Surgery, Taizhou Hospital, Zhejiang University, Taizhou, Zhejiang, 318000, China
Shen Haixing
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
Lu Yue
Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University, Huzhou, 313000, Zhejiang, China
Zheng Jingyan
Department of Breast and Thyroid Surgery, Lishui People’s Hospital, The Six Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, 323000, China
Fu Peifen
Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China
In cancer biology, the aberrant overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) has been correlative with an ominous prognosis, thereby underscoring its pivotal role in fostering metastatic progression. Consequently, EIF5A2 has garnered significant attention as a compelling prognostic biomarker for various malignancies. Our research endeavors were thus aimed at elucidating the utility and significance of EIF5A2 as a robust indicator of cancer outcome prediction.
